652 related articles for article (PubMed ID: 27956123)
21. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
[TBL] [Abstract][Full Text] [Related]
22. [Osteonecrosis of the jaw].
Drozdzowska B
Endokrynol Pol; 2011; 62 Suppl 3():4-9. PubMed ID: 22161980
[TBL] [Abstract][Full Text] [Related]
23. Bisphosphonate-associated osteonecrosis of the jaw in Ontario: a survey of oral and maxillofacial surgeons.
Khan AA; Rios LP; Sándor GK; Khan N; Peters E; Rahman MO; Clokie CM; Dore E; Dubois S
J Rheumatol; 2011 Jul; 38(7):1396-402. PubMed ID: 21498483
[TBL] [Abstract][Full Text] [Related]
24. [Evaluation of healing time of osteochemonecrosis of the jaw after surgery: Single-center retrospective study and review of the literature].
Berquet A; Louvrier A; Denis F; Bornert F; Weber E; Meyer C
J Stomatol Oral Maxillofac Surg; 2017 Feb; 118(1):11-19. PubMed ID: 28330568
[TBL] [Abstract][Full Text] [Related]
25. Bisphosphonate associated osteonecrosis of the jaw.
Khan AA; Sándor GK; Dore E; Morrison AD; Alsahli M; Amin F; Peters E; Hanley DA; Chaudry SR; Lentle B; Dempster DW; Glorieux FH; Neville AJ; Talwar RM; Clokie CM; Mardini MA; Paul T; Khosla S; Josse RG; Sutherland S; Lam DK; Carmichael RP; Blanas N; Kendler D; Petak S; Ste-Marie LG; Brown J; Evans AW; Rios L; Compston JE;
J Rheumatol; 2009 Mar; 36(3):478-90. PubMed ID: 19286860
[TBL] [Abstract][Full Text] [Related]
26. Epidemiology and pathogenesis of osteonecrosis of the jaw.
Reid IR; Cornish J
Nat Rev Rheumatol; 2011 Nov; 8(2):90-6. PubMed ID: 22124271
[TBL] [Abstract][Full Text] [Related]
27. Denosumab, an Alternative to Bisphosphonates but also Associated with Osteonecrosis of the Jaw--What is the Risk?
Sidhu HK
Dent Update; 2015 Jun; 42(5):436-8, 440. PubMed ID: 26964445
[TBL] [Abstract][Full Text] [Related]
28. [Bisphosphonate and denosumab-related osteonecrosis of the jaw: Epidemiology, diagnosis and management].
Dupic G; Collangettes D; Dillies AF; Calvet L; Tournilhac O; Bay JO; Mahammedi H
Bull Cancer; 2015 Dec; 102(12):1010-9. PubMed ID: 26607453
[TBL] [Abstract][Full Text] [Related]
29. Osteonecrosis of the jaw induced by receptor activator of nuclear factor-kappa B ligand (Denosumab) - Review.
de Oliveira CC; Brizeno LA; de Sousa FB; Mota MR; Alves AP
Med Oral Patol Oral Cir Bucal; 2016 Jul; 21(4):e431-9. PubMed ID: 26827069
[TBL] [Abstract][Full Text] [Related]
30. Denosumab-related osteonecrosis of the jaw: a case report and management based on pharmacokinetics.
You Tm; Lee KH; Lee SH; Park W
Oral Surg Oral Med Oral Pathol Oral Radiol; 2015 Nov; 120(5):548-53. PubMed ID: 26337218
[TBL] [Abstract][Full Text] [Related]
31. Gradual, but Not Sudden, Dose-Dependent Increase of ONJ Risk With Bisphosphonate Exposure: A Nationwide Cohort Study in Women With Osteoporosis.
Park JH; Kwoen MJ; Lee JR; Kim KS; Lee HJ; Kim JW; Lee H
Front Endocrinol (Lausanne); 2021; 12():774820. PubMed ID: 34956086
[TBL] [Abstract][Full Text] [Related]
32. Assessing the risk of osteonecrosis of the jaw due to bisphosphonate therapy in the secondary prevention of osteoporotic fractures.
Lapi F; Cipriani F; Caputi AP; Corrao G; Vaccheri A; Sturkenboom MC; Di Bari M; Gregori D; Carle F; Staniscia T; Vestri A; Brandi M; Fusco V; Campisi G; Mazzaglia G;
Osteoporos Int; 2013 Feb; 24(2):697-705. PubMed ID: 22618266
[TBL] [Abstract][Full Text] [Related]
33. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.
Saad F; Brown JE; Van Poznak C; Ibrahim T; Stemmer SM; Stopeck AT; Diel IJ; Takahashi S; Shore N; Henry DH; Barrios CH; Facon T; Senecal F; Fizazi K; Zhou L; Daniels A; Carrière P; Dansey R
Ann Oncol; 2012 May; 23(5):1341-1347. PubMed ID: 21986094
[TBL] [Abstract][Full Text] [Related]
34. [Osteonecrosis of the jaws (ONJ) associated to antiresorptive treatment].
Larsson Wexell C; Kjellman A; Akre O
Lakartidningen; 2018 May; 115():. PubMed ID: 29809272
[TBL] [Abstract][Full Text] [Related]
35. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.
Mavrokokki T; Cheng A; Stein B; Goss A
J Oral Maxillofac Surg; 2007 Mar; 65(3):415-23. PubMed ID: 17307586
[TBL] [Abstract][Full Text] [Related]
36. Osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF) in an osteoporotic patient chronically treated with bisphosphonates.
Sánchez A; Blanco R
Osteoporos Int; 2017 Mar; 28(3):1145-1147. PubMed ID: 27866217
[TBL] [Abstract][Full Text] [Related]
37. Antiresorptives and osteonecrosis of the jaw.
Yamashita J; McCauley LK
J Evid Based Dent Pract; 2012 Sep; 12(3 Suppl):233-47. PubMed ID: 23040351
[TBL] [Abstract][Full Text] [Related]
38. A multicenter case registry study on medication-related osteonecrosis of the jaw in patients with advanced cancer.
Schiodt M; Vadhan-Raj S; Chambers MS; Nicolatou-Galitis O; Politis C; Coropciuc R; Fedele S; Jandial D; Zhang J; Ma H; Saunders DP
Support Care Cancer; 2018 Jun; 26(6):1905-1915. PubMed ID: 29275525
[TBL] [Abstract][Full Text] [Related]
39. Medication-related osteonecrosis of the jaw associated with bisphosphonates and denosumab in osteoporosis.
Bagan J; Peydró A; Calvo J; Leopoldo M; Jiménez Y; Bagan L
Oral Dis; 2016 May; 22(4):324-9. PubMed ID: 26818808
[TBL] [Abstract][Full Text] [Related]
40. Bisphosphonate-associated osteonecrosis of the jaw, with healing after teriparatide: a review of the literature and a case report.
Narongroeknawin P; Danila MI; Humphreys LG; Barasch A; Curtis JR
Spec Care Dentist; 2010; 30(2):77-82. PubMed ID: 20415805
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]